## **CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPLICATION NUMBER: NDA 19787/S011** 

**CHEMISTRY REVIEW(S)** 

NORVASC FEB - 7 1996

CHEMIST'S REVIEW	1. ORGANIZATION HFD - 110		2. NDA Number 19-787
3. Name and Address of Applicant (City & State)			4. Supplement(s) Number(s)
Pfizer, Inc. 235 East 42nd Street New York, NY 10017-5755			S-011 <b>Date(s)</b> 01-22-96
5. <b>Drug Name</b> NORVASC	6. Nonproprietary Name Amlodipine Besylate		8. Amendments & Other (reports,
7. Supplement Provides Requesting the appr for	etc) - Dates		
9. Pharmacological Category Antihypertensive and Antianginal		10. How Dispensed	11. Related IND(s)/ NDA(s)/DMF(s)
12. Dosage Form(s) Tablet			
14. Chemical Name and Structure  3-Ethyl-5-methyl-2-(2-aminoethoxymethl)-4-(2-			15. Records/Reports Current
chlorophenyl)-1,4-dihydro-6-methyl-3,5- pyridinedicarboxylate benzenesulfonic acid			/x/ Yes /// No
\$0gH			
Hacozc cozcHzcHa			Reviewed
H <sub>3</sub> C N CH <sub>2</sub> OCH <sub>2</sub> CH <sub>2</sub> NH <sub>2</sub>			/x / Yes / / No
16. Comments:			
The applicant requested approval of a packaging site change for is an approved contract packager for this NDA. The new site is located at An authorization letter to refer to was provided. The applicant also submitted a stability commitment.			
17. Conclusions and Recommendations:			
An EER request for this facility was submitted by Kathleen E. Jongedyk for NDA 19-614/S-017 on 07/31/95 and was approved on 01/22/96. A copy of the acceptable status is enclosed. Since, the status of this facility is acceptable and this supplement is recommended for approval. An approval letter is being sent to the applicant.			
18. REVIEWER -			
Name Ramsharan D. Mittal	Signature	/\$/	Date Completed 02/01/96
19. Distribution:/ Original Jacket/ Reviewer/ Division File / / CSO			

15/ 2/1/96